CliffBio
biologic

Empliciti

elotuzumab

Loss of exclusivityNovember 2027projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameEmpliciti
Active ingredientelotuzumab
Strength400MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2015
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Empliciti patent cliff — loss of exclusivity November 2027 | CliffBio